Multiplication of alpha-fetoprotein and protein induced by vitamin K absence-II is a powerful predictor of prognosis and recurrence in hepatocellular carcinoma patients after a hepatectomy

Hepatology Research

Volumn 45, Issue 10, 2015, Pages E21-E31

  Kamiyama, Toshiya ^a   Yokoo, Hideki ^a   Kakisaka, Tatsuhiko ^a   Orimo, Tatsuya ^a   Wakayama, Kenji ^a   Kamachi, Hirofumi ^a   Tsuruga, Yosuke ^a   Yamashita, Kenichiro ^a   Shimamura, Tsuyoshi ^b   Todo, Satoru ^a   Taketomi, Akinobu ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Alpha fetoprotein; Hepatectomy; Hepatocellular carcinoma; Prognosis; Protein induced by vitamin K absence or antagonists II; Recurrence

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG; VITAMIN K ANTAGONISM FACTOR II;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PORTAL VEIN; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL; RISK FACTOR; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR INVASION; VERY ELDERLY;

EID: 84945460216     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12451     Document Type: Article

References (31)

1. Arii S, Yamaoka Y, Futagawa S etal. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32 (6): 1224-1229.
2. Kamiyama T, Nakanishi K, Yokoo H etal. Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol 2009; 16 (6): 1560-1571.
3. Ikai I, Arii S, Kojiro M etal. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101 (4): 796-802.
4. Sasaki Y, Yamada T, Tanaka H etal. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 2006; 244 (5): 771-780.
5. Jonas S, Bechstein WO, Steinmuller T etal. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33 (5): 1080-1086.
6. Shirabe K, Itoh S, Yoshizumi T etal. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007; 95 (3): 235-240.
7. Shimada M, Takenaka K, Fujiwara Y etal. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 1996; 78 (10): 2094-2100.
8. Tamura S, Kato T, Berho M etal. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001; 136 (1): 25-30.
9. Toyoda H, Kumada T, Kiriyama S etal. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4 (1): 111-117.
10. Imamura H, Matsuyama Y, Tanaka E etal. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38 (2): 200-207.
11. Izumi R, Shimizu K, Ii T etal. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994; 106 (3): 720-727.
12. Kondo K, Chijiiwa K, Makino I etal. Risk factors for early death after liver resection in patients with solitary hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2005; 12 (5): 399-404.
13. Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 1991; 14 (5): 802-805.
14. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989; 64 (8): 1700-1707.
15. Hanazaki K, Kajikawa S, Koide N, Adachi W, Amano J. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol 2001; 96 (4): 1243-1250.
16. Matsumoto Y, Suzuki T, Asada I, Ozawa K, Tobe T, Honjo I. Clinical classification of hepatoma in Japan according to serial changes in serum alpha-fetoprotein levels. Cancer 1982; 49 (2): 354-360.
17. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood) 2001; 226 (5): 377-408.
18. Silver HK, Gold P, Shuster J, Javitt NB, Freedman SO, Finlayson ND. Alpha(1)-fetoprotein in chronic liver disease. N Engl J Med 1974; 291 (10): 506-508.
19. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62 (Suppl 1): 57-63.
20. Kasahara A, Hayashi N, Fusamoto H etal. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993; 38 (12): 2170-2176.
21. Ikoma J, Kaito M, Ishihara T etal. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002; 49 (43): 235-238.
22. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82 (9): 1643-1648.
23. Inoue S, Nakao A, Harada A, Nonami T, Takagi H. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma. Am J Gastroenterol 1994; 89 (12): 2222-2226.
24. Koike Y, Shiratori Y, Sato S etal. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91 (3): 561-569.
25. Sumie S, Kuromatsu R, Okuda K etal. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008; 15 (5): 1375-1382.
26. Kaibori M, Matsui Y, Yanagida H, Yokoigawa N, Kwon AH, Kamiyama Y. Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma. World J Surg 2004; 28 (7): 702-707.
27. Kiriyama S, Uchiyama K, Ueno M etal. Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival. Ann Surg 2011; 254 (6): 984-991.
28. Figueras J, Jaurrieta E, Valls C etal. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 2000; 190 (5): 580-587.
29. Otto G, Heuschen U, Hofmann WJ, Krumm G, Hinz U, Herfarth C. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis. Ann Surg 1998; 227 (3): 424-432.
30. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 2007; 245 (1): 51-58.
31. Shimoda M, Ghobrial RM, Carmody IC etal. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl 2004; 10 (12): 1478-1486.